ACELYRIN announced that data from its Phase 1/2 clinical trial of lonigutamab in thyroid eye disease will be shared in a rapid-fire oral presentation at the 42nd Annual Meeting of the European Society of Ophthalmic Plastic and Reconstructive Surgery taking place from September 12-14, 2024 in Rotterdam, Netherlands. “The rapid suppression of IGF-1 receptor signaling observed with lonigutamab could potentially improve clinical outcomes for patients by achieving robust clinical responses with low drug exposures,” said Shephard Mpofu, M.D., Chief Medical Officer of ACELYRIN. “Importantly, we believe these data are supportive of the potential for subcutaneously-delivered lonigutamab to provide deep and durable responses with convenient, self-administered dosing.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLRN:
- ACELYRIN, INC. to Participate in Upcoming Investor Conferences
- Acelyrin price target lowered to $6 from $13 at Morgan Stanley
- Mars buys Kellanova, Cardinal Health reports Q4 beat: Morning Buzz
- Acelyrin price target lowered to $20 from $68 at Piper Sandler
- Acelyrin downgraded to Neutral from Buy at H.C. Wainwright